Package 69097-362-02

{"route": ["ORAL"], "spl_id": "1a48f22b-e37b-4221-9f99-a9e149279630", "openfda": {"nui": ["N0000175656", "N0000175462", "N0000009947"], "unii": ["J220T4J9Q2", "2T8Q726O95"], "rxcui": ["602393"], "spl_set_id": ["c0488bee-2f18-4e2e-8e11-68543c023dec"], "pharm_class_epc": ["Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]"], "pharm_class_moa": ["Nucleoside Reverse Transcriptase Inhibitors [MoA]"], "manufacturer_name": ["Cipla USA Inc."], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "30 TABLET, FILM COATED in 1 BOTTLE (69097-362-02)", "package_ndc": "69097-362-02", "marketing_start_date": "20170329"}], "brand_name": "Abacavir and Lamivudine", "product_id": "69097-362_1a48f22b-e37b-4221-9f99-a9e149279630", "dosage_form": "TABLET, FILM COATED", "pharm_class": ["Cytochrome P450 1A1 Inhibitors [MoA]", "Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Nucleoside Reverse Transcriptase Inhibitors [MoA]", "Nucleoside Reverse Transcriptase Inhibitors [MoA]"], "product_ndc": "69097-362", "generic_name": "Abacavir and lamivudine", "labeler_name": "Cipla USA Inc.", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Abacavir and Lamivudine", "active_ingredients": [{"name": "ABACAVIR SULFATE", "strength": "600 mg/1"}, {"name": "LAMIVUDINE", "strength": "300 mg/1"}], "application_number": "ANDA091144", "marketing_category": "ANDA", "marketing_start_date": "20170328", "listing_expiration_date": "20261231"}